BioNTech Phase 3 trial of variant-adapted BNT162b2 COVID vaccine recruitingSep 30Weekly roundup, 7 itemsatirmociclibberobenatide
CHMP backs two AstraZeneca drugs: Klygefa in gMG, Enhertu in early breast cancerSep 21Regulatory milestoneAstraZenecafam-trastuzumab deruxtecan-nxki
EU clears Enhertu plus pertuzumab as first-line HER2-positive metastatic breast cancer therapyAug 31Regulatory decisionAstraZenecafam-trastuzumab deruxtecan-nxki
FDA approves Ziihera-based regimens for first-line HER2+ gastroesophageal cancerAug 25Regulatory decisionBeiGeneJazz Pharmaceuticals
BeyondSpring updates Plinabulin data, names new CEO, reports Q2 2026 resultsAug 14Quarterly updateBeyondSpring Pharmaceuticals Inc.
BridgeBio Oncology reports Q2 2026 results, starts two KRAS inhibitor combination trialsAug 11Quarterly updateBridgeBio Oncology Therapeutics, Inc.
ALX Oncology posts Q2 2026 results, reaffirms mid-2027 ASPEN-09-Breast readoutAug 6Quarterly updateALX Oncology Inc.
BeOne Medicines reports Q2 2026 results, raises full-year revenue guidanceAug 5Quarterly updateBeiGenesonrotoclax
Ocrevus higher-dose Phase 3 posts results, misses primary endpoint; two partner trials updateJul 24Weekly roundup, 4 itemsobinutuzumabocrelizumab
AstraZeneca posts NATRON Phase III benralizumab results; registers ROSY-S anifrolumab rollover studyJul 10Weekly roundup, 9 itemsanifrolumab-fniaAstraZeneca
Lilly posts SURPASS-CVOT results; tirzepatide compared to dulaglutide on cardiovascular eventsJul 10Weekly roundup, 8 itemsAstraZenecabaricitinib
Novartis: Mayzent label update approved; four real-world studies registered or recruitingJul 2Weekly roundup, 7 itemsalpelisibFludarabine
EU approves Enhertu as first tumor-agnostic HER2-directed ADCJun 29Regulatory decisionAstraZenecafam-trastuzumab deruxtecan-nxki
Sign inSign in